(redirected from Claritin reditabs)
Also found in: Dictionary.


a nonsedating antihistamine (H1 receptor antagonist) used for treatment of allergic rhinitis and chronic idiopathic urticaria and as a treatment adjunct in asthma; administered orally.


Aerius (CA), Alavert, Allertin, Claritin, Claritin RediTabs, Clarityn (UK)

Pharmacologic class: Histamine1-receptor antagonist (second-generation)

Therapeutic class: Antihistamine (nonsedating)

Pregnancy risk category B


Selective histamine1-receptor antagonist. Blocks peripheral effects of histamine release during allergic reactions, decreasing or preventing allergy symptoms.


Syrup: 1 mg/ml

Tablets: 10 mg

Tablets (rapidly disintegrating): 10 mg

Indications and dosages

Seasonal allergies; chronic idiopathic urticaria

Adults and children ages 6 and older: 10 mg P.O. daily

Children ages 2 to 5: 5 mg P.O. daily

Dosage adjustment

• Renal or hepatic impairment


• Hypersensitivity to drug


Use cautiously in:
• renal or hepatic impairment
• elderly patients
• pregnant patients
• children younger than age 2 (safety not established).


• Give once a day on empty stomach.
• Place rapidly disintegrating tablet on tongue; give with or without water.
• Use rapidly disintegrating tablets within 6 months of opening foil pouch and immediately after opening individual tablet blister.

Adverse reactions

CNS: headache, nervousness, insomnia

EENT: conjunctivitis, earache, epistaxis, pharyngitis

GI: abdominal pain; dry mouth; diarrhea, stomatitis (in children)

Skin: rash, photosensitivity, angioedema

Other: tooth disorder (in children), fever, flulike symptoms, viral infections


Drug-food.Any food: increased drug absorption

Patient monitoring

• Watch for adverse reactions, especially in children.
• Assess patient's response to drug.
• Watch for new symptoms or exacerbation of existing symptoms.

Patient teaching

• Advise patient to take exactly as prescribed, once a day on empty stomach.
• Tell patient to report persistent or worsening symptoms.
• Instruct patient to report adverse reactions, such as headache or nervousness.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the foods mentioned above.


/lor·at·a·dine/ (lah-rat´ah-dēn) a nonsedating antihistamine used in the treatment of allergic rhinitis, chronic idiopathic urticaria, and asthma.


A nonsedating antihistamine, C22H23ClN2O2, used to treat allergic rhinitis and other allergic disorders.


a nonsedating antihistamine (H1-receptor antagonist) used for treatment of allergic rhinitis and chronic idiopathic urticaria and as a treatment adjunct in asthma, administered orally.


An ANTIHISTAMINE drug used to treat hay fever and other allergic disorders.


Any substance that reduces the effect of histamine or blocks histamine receptors, usually the histamine 1 (H1) receptor. It is used in the treatment of allergic conjunctivitis and also in the temporary relief of minor allergic symptoms of the eye. Common agents include antazoline sulfate, azelastine hydrochloride, cetirizine, chlorphenamine, emedastine, epinastine hydrochloride, ketotifen, levocabastine, loratadine and olopatadine. See hypersensitivity; mast cell stabilizers.


n brand name: Claritin;
drug class: antihistamine, H1 histamine antagonist;
action: acts on blood vessels, gastrointestinal system, respiratory system by competing with histamine for H1-receptor site; decreases allergic response by blocking histamine;
uses: seasonal rhinitis, allergy symptoms, idiopathic chronic urticaria.
References in periodicals archive ?
To settle civil False Claims Act liabilities, Schering-Plough will pay $255 million for misreporting its best price of Claritin RediTabs and K-Dur to avoid paying Medicaid rebates (thereby overcharging Public Health Service programs); paying physicians to prescribe Intron A and Temodar; and promoting Temodar for certain brain tumors and brain metastases and Intron A for superficial bladder cancer--off-label uses not approved by the FDA.
Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the Company's dependence on a relatively small number of products, licensing revenues, the timing and outcome of litigation and future product launches, including its bioequivalent version of Claritin RediTabs, government regulation, competition, and manufacturing results.
Investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to, the Company's ability to gain approval for its bioequivalent versions of Claritin-D 12 and Claritin Reditabs, Andrx's ability to manufacture and Perrigo's ability to market the Company's bioequivalent versions of Claritin D-24, Claritin-D 12 and Claritin Reditabs, as well as Andrx's results of operations.
According to this regulation, the 180-day period of market exclusivity would commence following the earlier of two events: Wyeth's market launch of this product or a final court ruling in the patent infringement litigation, stipulating that the Claritin RediTabs patent is invalid or will not be infringed by a generic version.
In December 2002, Wyeth Consumer Healthcare received FDA approval for its New Drug Application (NDA) for Alavert(TM), an over-the-counter fast-dissolve formulation of Claritin RediTabs.
The most significant of Andrx's product candidates are Wellbutrin SR/Zyban, Tiazac and the Claritin family of products (Claritin-D 24 Hour, Claritin-D 12, and Claritin Reditabs, all of which have been converted into OTC products by the brand holder).
The FDA granted final marketing approval for Claritin-D 24 in February 2003, and to the Company's knowledge, the only substantive matter delaying approval of Andrx's bioequivalent versions of Claritin D-12 and Claritin Reditabs is the expiration of the 180-day market exclusivity period for each of those products.
Andrx expects to receive final FDA marketing approval on its bioequivalent versions of Claritin-D 12 and Claritin Reditabs following the expiration of the exclusivity periods of other generic manufacturers.
Claritin-D 12 Hour, Claritin RediTabs and Claritin-D 24 Hour are registered trademarks of Schering-Plough Corporation.
The Andrx ANDA for a bioequivalent version of Claritin Reditabs remains the subject of patent infringement litigation initiated by Schering-Plough.
Schering markets Claritin Reditabs for the relief of symptoms of seasonal allergic rhinitis (hayfever).
sales of Claritin Reditabs were approximately $225 million during the 12-month period ending June 30, 2000.